RU2257383C2 - Лечение эмфиземы с помощью ретиноидных агонистов (rar), обладающих избирательным действием - Google Patents

Лечение эмфиземы с помощью ретиноидных агонистов (rar), обладающих избирательным действием Download PDF

Info

Publication number
RU2257383C2
RU2257383C2 RU2002110289/04A RU2002110289A RU2257383C2 RU 2257383 C2 RU2257383 C2 RU 2257383C2 RU 2002110289/04 A RU2002110289/04 A RU 2002110289/04A RU 2002110289 A RU2002110289 A RU 2002110289A RU 2257383 C2 RU2257383 C2 RU 2257383C2
Authority
RU
Russia
Prior art keywords
alkyl
rarγ
group
agonist
rar
Prior art date
Application number
RU2002110289/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2002110289A (ru
Inventor
Пола Нанетт БЕЛЛОНИ (US)
Пола Нанетт БЕЛЛОНИ
Михаэль КЛАУС (DE)
Михаэль КЛАУС
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2002110289A publication Critical patent/RU2002110289A/ru
Application granted granted Critical
Publication of RU2257383C2 publication Critical patent/RU2257383C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2002110289/04A 1999-10-19 2000-10-13 Лечение эмфиземы с помощью ретиноидных агонистов (rar), обладающих избирательным действием RU2257383C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19
US60/160,415 1999-10-19

Publications (2)

Publication Number Publication Date
RU2002110289A RU2002110289A (ru) 2003-12-10
RU2257383C2 true RU2257383C2 (ru) 2005-07-27

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002110289/04A RU2257383C2 (ru) 1999-10-19 2000-10-13 Лечение эмфиземы с помощью ретиноидных агонистов (rar), обладающих избирательным действием

Country Status (33)

Country Link
US (1) US6300350B1 (enExample)
EP (1) EP1225878B1 (enExample)
JP (2) JP4074458B2 (enExample)
KR (1) KR100485581B1 (enExample)
CN (1) CN1201730C (enExample)
AR (1) AR029648A1 (enExample)
AT (1) ATE344661T1 (enExample)
AU (1) AU777325B2 (enExample)
BR (1) BR0015225A (enExample)
CA (1) CA2387844C (enExample)
CY (1) CY1105941T1 (enExample)
CZ (1) CZ20021657A3 (enExample)
DE (1) DE60031790T2 (enExample)
DK (1) DK1225878T3 (enExample)
ES (1) ES2274810T3 (enExample)
HR (1) HRP20020329A2 (enExample)
HU (1) HUP0203295A3 (enExample)
IL (1) IL149151A0 (enExample)
JO (1) JO2178B1 (enExample)
MA (1) MA26835A1 (enExample)
MX (1) MXPA02003843A (enExample)
MY (1) MY129001A (enExample)
NO (1) NO328738B1 (enExample)
NZ (1) NZ518118A (enExample)
PE (1) PE20010678A1 (enExample)
PL (1) PL357499A1 (enExample)
PT (1) PT1225878E (enExample)
RS (1) RS50165B (enExample)
RU (1) RU2257383C2 (enExample)
TR (1) TR200201071T2 (enExample)
TW (1) TWI288639B (enExample)
WO (1) WO2001030326A1 (enExample)
ZA (1) ZA200202576B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
WO2003024921A1 (en) 2001-09-18 2003-03-27 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
ATE427929T1 (de) 2001-09-18 2009-04-15 Hoffmann La Roche Substituierte harnstoff retinoid agonisten ii
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
ES2481167T3 (es) 2003-08-22 2014-07-29 Dupont Nutrition Biosciences Aps Composición que comprende una bacteriocina y un extracto de una planta de la familia Labiatae
WO2008063842A2 (en) * 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
BR112013004685B1 (pt) 2010-09-01 2021-09-21 Thomas Jefferson University Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular
US9949996B2 (en) 2011-06-24 2018-04-24 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013019653A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
AU2013363215B2 (en) 2012-12-17 2018-03-01 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
SI2931713T1 (sl) 2012-12-17 2017-03-31 Parion Sciences, Inc. Derivati kloro-pirazin karboksamida uporabni za zdravljenje bolezni favoriziranih z nezadostno hidracijo sluznice
US9963439B2 (en) 2013-08-20 2018-05-08 University Of Washington Through Its Center For Commercialization Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase
EP3039126B1 (en) 2013-08-26 2019-10-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700836A (en) * 1993-09-02 1997-12-23 Hoffmann-La Roche Inc. Aromatic carboxylic acid derivatives
RU96103662A (ru) * 1995-02-24 1998-05-10 Ф. Хоффманн-Ля Рош Аг Новые ретиноиды
RU2129556C1 (ru) * 1993-08-19 1999-04-27 Жансен Фармасетика Н.В. Производное дигидробензопирана, обладающее сосудосуживающим действием, промежуточные соединения, способы получения, фармацевтическая композиция и способ ее получения
WO1999045915A1 (en) * 1998-03-09 1999-09-16 F. Hoffmann-La Roche Ag Use of alpha-rar antagonists for inhibition of mucin secretion

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0139216B1 (ko) * 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
ATE185799T1 (de) * 1995-02-24 1999-11-15 Hoffmann La Roche Retinoide
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
ATE334673T1 (de) * 1997-11-12 2006-08-15 Hoffmann La Roche Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
WO2000061232A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
AU4222400A (en) 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
MXPA02000828A (es) * 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2129556C1 (ru) * 1993-08-19 1999-04-27 Жансен Фармасетика Н.В. Производное дигидробензопирана, обладающее сосудосуживающим действием, промежуточные соединения, способы получения, фармацевтическая композиция и способ ее получения
US5700836A (en) * 1993-09-02 1997-12-23 Hoffmann-La Roche Inc. Aromatic carboxylic acid derivatives
RU96103662A (ru) * 1995-02-24 1998-05-10 Ф. Хоффманн-Ля Рош Аг Новые ретиноиды
RU96111015A (ru) * 1995-06-05 1998-09-27 Бристоль-Мейерз Сквибб Компани Ретиноидоподобные соединения
WO1999045915A1 (en) * 1998-03-09 1999-09-16 F. Hoffmann-La Roche Ag Use of alpha-rar antagonists for inhibition of mucin secretion

Also Published As

Publication number Publication date
TWI288639B (en) 2007-10-21
DE60031790D1 (de) 2006-12-21
NO20021823L (no) 2002-04-18
JP2003512418A (ja) 2003-04-02
EP1225878A1 (en) 2002-07-31
AU777325B2 (en) 2004-10-14
BR0015225A (pt) 2002-07-16
US6300350B1 (en) 2001-10-09
JP2007302689A (ja) 2007-11-22
AR029648A1 (es) 2003-07-10
CN1382042A (zh) 2002-11-27
JO2178B1 (en) 2003-04-23
HUP0203295A3 (en) 2003-04-28
WO2001030326A1 (en) 2001-05-03
YU29002A (sh) 2005-06-10
HRP20020329A2 (en) 2004-04-30
KR100485581B1 (ko) 2005-04-27
CY1105941T1 (el) 2011-04-06
RS50165B (sr) 2009-05-06
DE60031790T2 (de) 2007-09-20
IL149151A0 (en) 2002-11-10
JP4850791B2 (ja) 2012-01-11
TR200201071T2 (tr) 2002-08-21
NZ518118A (en) 2004-02-27
CZ20021657A3 (cs) 2002-10-16
CA2387844C (en) 2009-04-14
ATE344661T1 (de) 2006-11-15
PT1225878E (pt) 2007-01-31
MA26835A1 (fr) 2004-12-20
HK1051002A1 (zh) 2003-07-18
KR20020043640A (ko) 2002-06-10
AU1137401A (en) 2001-05-08
DK1225878T3 (da) 2007-03-05
MXPA02003843A (es) 2002-09-30
CA2387844A1 (en) 2001-05-03
MY129001A (en) 2007-03-30
ZA200202576B (en) 2003-09-23
PE20010678A1 (es) 2001-07-04
PL357499A1 (pl) 2004-07-26
HUP0203295A2 (hu) 2003-01-28
ES2274810T3 (es) 2007-06-01
NO20021823D0 (no) 2002-04-18
NO328738B1 (no) 2010-05-03
CN1201730C (zh) 2005-05-18
JP4074458B2 (ja) 2008-04-09
EP1225878B1 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
JP4850791B2 (ja) Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療
CA2372231C (en) Aerosol formulations and devices for increasing libido in women via acute testosterone administration
EP1216046B1 (de) Neue kombination von loteprednol und antihistaminika
JPH013193A (ja) 細胞、組織修復剤
DE60130661T2 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
CN119606938A (zh) 绿原酸在制备预防和治疗主动脉夹层药物中的应用
KR20010041720A (ko) 뮤신의 분비를 저해하기 위한 알파-레티노산 수용체길항제의 용도
CN119055627A (zh) 绿原酸在制备预防和治疗主动脉夹层药物中的应用
KR20010083123A (ko) 알레르기 질환 치료제
US20150071880A1 (en) Treatment of epithelial layer lesions
JP2021176903A5 (enExample)
DE60210804T2 (de) Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit
US20060128738A1 (en) Treatment of interstitial cystitis using cannabinoid analogs
EP3443954A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof and use in preparing drugs for treating respiratory system diseases
HK40082364A (en) Topical formulations comprising combinations of montelukast and mussel adhesion proteins
DE60305592T2 (de) Liposomenhaltiges Mittel zur Behandlung Gefässerkrankungen
HK40011773A (en) Anti-inflammatory use of peptide
US20120295982A1 (en) Treating human male copd patients with oral bedoradrine

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20111014